Furthermore, membranous expression of PRPF38B was significantly associated with a poor prognosis at the 5 year follow-up in patients with ER-negative/HER2-positive breast cancer who were treated prior to 2006 and did not receive trastuzumab therapy. The gene discussed is ERBB2; the disease is breast cancer.